Passer au contenu principal
Centre intégré universitaire de santé
et de services sociaux de l'Est-de-l'Île-de-Montréal

Centre intégré universitaire de santé et de services sociaux de l'Est-de-l'Île-de-Montréal

Jean-Philippe Lafrance

Lafrance, Jean-Philippe

Full Professor


Université de Montréal

Research Axes



  • Mukelda Mikye Castor
  • Karine Chaussé
  • Naoual Elftouh

Dr. Jean-Philippe Lafrance is a nephrologist and the principal investigator of the Pharmacoepidemiology of Kidney Disease Research Unit. He is also a Full Professor in the Department of Pharmacology and Physiology and the Faculty of Medicine at Université de Montréal.

His clinical and research activities focus on the pharmacoepidemiology of kidney disease and the epidemiology of dialysis complications.

Research Unit

Pharmacoepidemiology of Kidney Disease

Research interests

  • Renal side effects such as acute kidney failure due to the use of drugs commonly used by the general population (e.g., non-steroidal anti-inflammatory drugs)
  • Use and side effects of medication in patients with chronic kidney disease or who require dialysis
  • Epidemiology and risk factors for infectious complications in patients with end-stage kidney disease
  • Incidence, risk factors and consequences related to acute kidney failure in patients with chronic kidney failure
  • Pharmacokinetic studies in patients with moderate and severe kidney failure (phase I)
  • Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis. Lazrak HH, René É, Elftouh N, Leblanc M, Lafrance JP. BMC Nephrol. 2017 Jun 7;18(1):187. doi: 10.1186/s12882-017-0596-4.
    More detail
  • Association of erythropoiesis-stimulating agents and the incidence risk of cancer diagnosis among chronic dialysis patients: a nested case-control study. René É, Lazrak HH, Laurin LP, Elftouh N, Vallée M, Lafrance JP. Nephrol Dial Transplant. 2017 Jun 1;32(6):1047-1052. doi: 10.1093/ndt/gfw268.
    More detail
  • Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD. Lepage L, Dufour AC, Doiron J, Handfield K, Desforges K, Bell R, Vallée M, Savoie M, Perreault S, Laurin LP, Pichette V, Lafrance JP. Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2136-42. doi: 10.2215/CJN.03640415. Epub 2015 Nov 17.
    More detail
  • Serotonin-Norepinephrine Reuptake Inhibitors and the Risk of AKI: A Cohort Study of Eight Administrative Databases and Meta-Analysis. Renoux C, Lix LM, Patenaude V, Bresee LC, Paterson JM, Lafrance JP, Tamim H, Mahmud SM, Alsabbagh MW, Hemmelgarn B, Dormuth CR, Ernst P; Canadian Network of Observational Drug Effect Studies (CNODES) Investigators. Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1716-22. doi: 10.2215/CJN.11271114. Epub 2015 Jul 31.
    More detail
  • Association between acetylsalicylic acid and the risk of dialysis-related infections or septicemia among incident hemodialysis patients: a nested case-control study. Harrak H, Normand I, Grinker R, Elftouh N, Laurin LP, Lafrance JP. BMC Nephrol. 2015 Jul 28;16:115. doi: 10.1186/s12882-015-0112-7.
    More detail
  • Outcomes of Infection-Related Hospitalization according to Dialysis Modality. Laurin LP, Harrak H, Elftouh N, Ouimet D, Vallée M, Lafrance JP. Clin J Am Soc Nephrol. 2015 May 7;10(5):817-24. doi: 10.2215/CJN.09210914. Epub 2015 Mar 27.
    More detail
  • Trends in infection-related hospital admissions and impact of length of time on dialysis among patients on long-term dialysis: a retrospective cohort study. Lafrance JP, Rahme E, Iqbal S, Elftouh N, Laurin LP, Vallée M. CMAJ Open. 2014 May 23;2(2):E109-14. doi: 10.9778/cmajo.20120027. eCollection 2014 Apr.
    More detail
  • Association between vitamin D receptor activator and the risk of infection-related hospitalizations among incident hemodialysis patients: a nested case-control study. Normand I, Elftouh N, Laurin LP, Ouimet D, Harrak H, Lafrance JP. Pharmacoepidemiol Drug Saf. 2014 Mar;23(3):261-7. doi: 10.1002/pds.3576. Epub 2014 Jan 27.
    More detail
  • Magnitude of discordance between registry data and death certificate when evaluating leading causes of death in dialysis patients. Lafrance JP, Rahme E, Iqbal S, Leblanc M, Pichette V, Elftouh N, Vallée M. BMC Med Res Methodol. 2013 Mar 27;13:51. doi: 10.1186/1471-2288-13-51.
    More detail
  • Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, Lafrance JP, Levy A, Garg AX, Ernst P; Canadian Network for Observational Drug Effect Studies. BMJ. 2013 Mar 18;346:f880. doi: 10.1136/bmj.f880.
    More detail


  • Doctor of Medicine

    Université de Montréal

  • Internal medicine

    Royal College of Physicians and Surgeons of Canada, Internal Medicine (FRCPC)

  • Certificate in nephrology

    CSPQ and FRCPC

  • MSc in epidemiology

    McGill University

  • Postdoctoral fellowship in pharmacoepidemiology

    Boston University


  • 2016 Young nephrologist of the year  (Société québécoise de néphrologie)